We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Aortech International Plc | LSE:AOR | London | Ordinary Share | GB0033360586 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 126.50 | 123.00 | 130.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
12/2/2016 08:13 | SP - all interesting stuff. I have been watching Foldax and couldn't see that they had raised $2m recently - have you got a link. I would have thought they might have missed the boat with the biotech bubble now burst for silly valuations. Love your scenario though !! | harrogate | |
11/2/2016 21:16 | bbr I originally felt that the £2million (just over 3 million dollars) was raised to cover the pending court case and any potential damages.The way it was raised meant the Co did not need to disclose the reason for it convenient as I wouldnt think any would be investors would be happy risking their capital on potential future damages. I was also most surprised at how quickly this sum was raised by Foldax after seemingly struggling to raise a far smaller amount as start up capital. It makes me think they must have been working very closely with a friendly investor who was persuaded by Maguires strategy. The interesting question is what might MaGuires strategy be He could hope that he wins the court case and/ or Aor runs out of money I think both these scenarios are unlikely He could on the other hand go on the front foot and make a knockout bid for Elasteon conditional on Aor dropping the court case while retaining the valuable heart valve. It would appear Foldax might have a backer with deep pockets and they would need to pay a hefty premium for the current Aortech BOD to give them houseroom. However despite the obvious bad feeling between the parties this could be a deal that suits both and ultimately Aor shareholders would benefit Aor could sell Elasteon for a premium say up to £10 million (bearing in mind loss of potential damages of £2mill) and be free to float the heart valve project from a position of real strength. Maguires options would appear more limited but buying Elasteon would offer Foldax an out from a poential terminal situation freeing it from future litigation and allowing it a chance to develop its business. All this is guess work and assumes Aortech has the stronger legal case which I am convinced given time it will win but Foldax raised money for a reason and time is not on their side. Perhaps there is a deal to be done from a position of overwhelming strength in the interests of Aortech shareholders despite the understandable animosity The recent share volume would suggest something is going on but there are 2 parties that need to reach a settlement so could a deal be on the cards Your guess is as good as mine regards SP | spurious | |
11/2/2016 17:20 | But who sold 5% of the company ? | harrogate | |
11/2/2016 17:05 | gac 141 , Thankyou for the heads up . I only know what I have checked up online . Foldax Our other director raised £2 million thereabouts . I think that speaks volumes . Along with about 5% of the company bought at 26.5p . Should be inciteful enough. Despite market carnage . Things bode well .Dependant on how Honest our current BOD is . the technology we own is rocket science ( literally ). Even PJones would buy into these patents . Good luck And May | bbr391 | |
22/1/2016 13:49 | bbr391 - You seems a knowledgeable sort of guy...have you heard how the heart valve project is going? | gac141 | |
21/1/2016 23:44 | Still ongoing . | bbr391 | |
19/1/2016 09:18 | Anyone have any ideas on the legal action status please? | semper vigilans | |
06/12/2015 14:56 | Oh yes and when we all thought the writing was on the wall and Aortech was bust how much of your money did you chance David? This money saved Aortech.... | gac141 | |
06/12/2015 13:04 | I see Xmas coming early for loan note holders. Shocking really, but to be expected from AIM listed companies these days. | cocker | |
27/11/2015 12:40 | Very disappointing revenue figures below last years interims Lets hope litigation is not being used as an excuse for poor sales focus. Have to say I believe Harrogate has summed up the current situation very well in his previous post Let us hope the directors are fully focussed on unlocking shareholder value I do not think there has been any change in that potential value but we do need to stay in business long enough to unlock that value ! No more banana skins would be appreciated | spurious | |
18/11/2015 11:12 | why the sudden drop here, I wonder. No news about, no heavy selling that I'm aware of. MMs trying clear out weak holders before some good news is announced? Or have they got wind of bad news? Possibly it's neither.. just random market movements. | shrout | |
25/10/2015 08:30 | Yes......25th October seems to be a significant date! | tadders2 | |
25/10/2015 08:05 | AorTech International PLC v. Folda The case against the Ex . Should provide our next uplift . The future is bright as long as the current board play the cards right . Good luck all And May | bbr391 | |
16/9/2015 19:10 | Hi Gents - thanks for the notes - I am perhaps always as a long standing shareholder ( 1999) just too beaten up to believe all that yet - Hope you are right/ Thanks | harrogate | |
16/9/2015 11:08 | Harrogate As a fellow shareholder of longstanding (some may say long suffering)I understand your caution I am not noted for wild bouts of optimism particularly with Aor however I do recognise a fundamental shift both in sentiment and in what has been achieved over the last 12 months. I feel we are at an inflexion point for the share price which as we all know tends to anticipate events well in advance 12 month results pointed to a profitable stable company now crucially happy with its renegotiated relationship with Biomerics, confident in a ring fenced litigation process and now fully focused in releasing shareholder value through expanding its licencees and at long last attempting to realise the massive opportunity offered by its heart valve( backed by extensive patent protection). Let us wait for the evidence but the signs are already there. Once the evidence is out there the share price will imo be north of £1 and an opportunity missed. The tiny £2m current market cap imo offers a risk/reward ratio substantially in favour of the investor. That value is what I am trying to highlight.It would seem I am not alone Let us hope I am right Regards SP | spurious | |
16/9/2015 10:13 | Harrogate You are correct that there would appear to be masses of work to do, but reading the last statement would suggest that the outcome of that work should be positive. The IP position is better than 1999, there are 3 generations of patent filings since then some very recent. The key to value would seem to be can they identify a credible team to take the project forward? | landy90 | |
16/9/2015 09:35 | On Tip TV today.. After the crash Zak identifies the top 10 shares to buy TODAY for the autumn in his new book published 1st September. Get your free copy HERE Aortech International (AOR): 70p Price Channel Destination It has not exactly been a pleasant ride in terms of the daily chart progression over the past couple of years. This is a point witnessed by the decline seen from 130p plus in the autumn of 2013, to a probe below 20p in March. Since then there has been a rehabilitation process, one which has involved higher support points since the spring above 20p, and hen the recovery of the 50 day and 200 day moving averages both currently at 28p. The implication now in the wake of this extended base building is that the bulls should be happy to enjoy the latest golden cross buy signal between the 50 day and 200 day moving averages, with the message being that provided there is no end of day close back below these lines we should be wedded to the buy argument. Just how high the stock could fly over the next 1-2 months is suggested by the top of a rising trend channel, one which has been in place from as long ago as June last year. The best way forward on this basis would be to buy into Aortech International shares on any initial weakness which cools off the overbought RSI, now at 83. - See more at: | gac141 | |
16/9/2015 09:21 | It is great that we no longer seem to be at death's door but we should also not get carried away. The £3 share price of 3 years ago was really down to the value we felt we added to St Jude on the leads which turned out to be a complete illusion. My reading of the last RNS was that in terms of any real data on the heart valve we are back to 1999 almost and that there is a massive amount of work to do and won't any IP protection have lapsed by now? I also have not seen any evidence as you say above that " we are rapidly building turnover" there has been little evidence of new licenses of our technology. I am a lot more confident than I was 12 months ago but lots to do. Let's hope the management team are up to it - the are clearly good at fire fighting but that is a different kettle of fish. | harrogate | |
15/9/2015 11:08 | Hi George Whether we get an update on progress at the agm or whether that comes some weeks later I am confident we will get news confirming we are in an exciting new chapter built on solid profitable foundations As you point out people forget that the heart valve did represent a £32 million opportunity and if sold on to a major player after successful in house testing/validation/r So for a relatively modest outlay (borne by its partner) Aor could be sitting on a gold mine. A JV may be the best way to unlock the potential and ring fence costs while offering a share in future profits As Aor pointed out recently much of the testing has already been successfully carried out for the heart valve and it shows potential to be a world beater particularly due to the very significant cost savings over its rivals Aor highlighted the opportunity at results when it announced it was exploring ways of bringing a team together to develop the value Aor is now profitable and rapidly building turnover and profits from a stable/falling cost base Aor as a loss making Co enjoyed a share price in excess of £3 a couple of years ago and while I agree the share price is only a barometer of sentiment and expectation some of that optimism is now being realised in terms of real profits and opportunity The heart valve is in the share price for free so is the potential £1 mil outcome of the ongoing litigation against Mcguire We have a £2m market cap without the risk and negativity of previous years where we enjoyed a cap in excess of £10m as a loss maker with nil turnover Incredible ! Value will out Great time to be an Aor shareholder imo Best wishes SP | spurious | |
14/9/2015 22:19 | I hope you are right.. P I think we may have to be more patient... although any good news could move things very quickly. The building blocks have been put in place. | gac141 | |
14/9/2015 21:32 | Have to echo your sentiments George. I am hoping the agm this month may provide the ideal opportunity for some positive news. Just as the downside on the share price was greatly exaggerated, the corresponding effect on any positive news will be an equally swift and strong rise I am confident we will see a share price well in excess of £1 in a matter of weeks. Value will out | spurious |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions